Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Stock Is NosedivingShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...
Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results